Protalix BioTherapeutics, Inc.

Protalix is a commercial stage biopharmaceutical company that discovers, develops, produces, and commercializes therapeutics for rare diseases using a plant cell-based protein expression system. Its commercial portfolio includes two enzyme replacement therapies: Elelyso for Gaucher disease and Elfabrio for Fabry disease. In addition, the company develops pipeline candidates for conditions such as uncontrolled gout and renal indications. Rather than selling directly to individual patients, the company supplies drug substance and finished products to pharmaceutical partners, specifically Pfizer, Chiesi, and Fiocruz, which handle global distribution.

Geographically, the company's approved medicines are distributed across international markets. Elelyso is approved for commercial sale in more than 40 markets, including the United States, Brazil, and Israel. Elfabrio is authorized in the European Union, the United States, and more than 10 other jurisdictions. In addition, clinical studies and trial recruitment take place across several countries, including the United States, Israel, Georgia, and New Zealand. The provided report does not state where the company maintains its corporate headquarters.

Summary of the business section of Protalix BioTherapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 226 employees, all of whom are full time employees, and of which 25 have a Ph.D.”